genelabs
technologies
said
remains
schedule
announce
results
recently
completed
phase
iii
clinical
trial
gl701
lupus
end
second
quarter.the
company
working
closely
cooperatively
food
drug
administration
fda
complete
final
analysis
plan
subsequently
company
commence
analysis
clinical
data
